8 completed, 2 unknown, 1 terminated. 11 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 8, Unknown 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Mumps: new trials by email Literature Review of Mumps trials Research Report on Mumps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine - Measles; Mumps; Rubella; Chickenpox, Measles | Phase 2 | Completed | GlaxoSmithKline | 801 | 2022-12-14 | 2025-06-22 |
| Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11 Attenuated Mumps vaccine (KMB-17) in phase II and III, Placebo in phase II, Attenuated Mumps vaccine (KMB-17) in phase III - Epidemic Parotitis, Mumps | Phase 2 / Phase 3 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 11999 | 2020-10-12 | 2023-10-11 |
| Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants ≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old), ≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old), Measles and Mumps Combined Vaccine，Live(SIBP)( positive control) - Epidemic Parotitis,Mumps | Phase 2 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 1080 | 2017-05-20 | 2023-10-10 |
| Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation - Measles, Varicella | Phase 2 | Completed | GlaxoSmithKline | 501 | 2009-06-03 | 2019-11-15 |
| Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax® - Rubella, Mumps | Phase 2 | Completed | GlaxoSmithKline | 1259 | 2009-06-03 | 2020-01-03 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix® - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 1851 | 2007-11-20 | 2018-10-09 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ MeMuRu-OKA (study vac), MMR, Varicella vacc (control) - Mumps, Rubella | Phase 2 | Completed | GlaxoSmithKline | 400 | 2006-04-01 | 2016-10-07 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ MeMuRu-OKA (study vacc), MMR, Varicella vacc (control) - Varicella, Rubella | Phase 2 | Completed | GlaxoSmithKline | 446 | 2006-03-01 | 2016-10-07 |
| Immune Responses to Two Dose Varivax +/- MMR-II MMR-II, Pro-Quad, Varivax - Measles, Mumps | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 105 | 2005-10-01 | 2010-08-27 |
| Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live - Measles, Mumps | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1210 | 2001-12-01 | 2017-03-15 |
| ProQuad Dose Selection Study (V221-011)(COMPLETED) Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV - Measles, Mumps | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1551 | 1999-04-01 | 2015-04-10 |
Measles (9) · Rubella (9) · Chickenpox (8)
Infections (11) · Mononegavirales Infections (11) · Mouth Diseases (11) · Paramyxoviridae Infections (11) · Parotid Diseases (11) · Parotitis (11) · RNA Virus Infections (11) · Rubulavirus Infections (11) · Salivary Gland Diseases (11) · Stomatognathic Diseases (11) · Virus Diseases (11) · Morbillivirus Infections (9) · Rubivirus Infections (9) · Togaviridae Infections (9) · DNA Virus Infections (8)
measles, mumps, rubella, varicella vaccine (3) · Chickenpox Vaccine (2) · Hepatitis A Vaccines (2) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Clinical Trials, Phase II as Topic (1) · Clinical Trials, Phase III as Topic (1) · Measles-Mumps-Rubella Vaccine (1) · Mumps Vaccine (1) · Rubella Vaccine (1)
GlaxoSmithKline (6) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (4) · China (2) · Italy (2) · Puerto Rico (2) · Taiwan (2) · Canada (1) · Colombia (1) · France (1) · Germany (1) · Latvia (1) · Singapore (1)
Beifang Yang, PhD (1) · Qihan Li (1)